# OnCo record nct06445972 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06445972/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06445972", "NCT06445972" ;
  schema:name "Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)"@en ;
  schema:description "A phase 1/2 trial of Ramucirumab and Sacituzumab tirumotecan in gastric & gastro-oesophageal junction cancer and oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06445972/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06445972> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-08-07" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/esophageal/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/daiichi-sankyo/> .